Alector公司和葛兰素史克(GSK)公司近日宣布建立合作伙伴关系,共同开发两种促进progranulin(颗粒蛋白前体,PGRN)蛋白质生产的实验性抗体——AL001和AL101——作为肌萎缩侧索硬化症(ALS)等神经退行性疾病的潜在治疗药物。 根据合作协议,Alector将获得高达22亿美元的付款,并在2期概念验证研究期间继续负责AL001和AL101的临床...
Alector is set to lead the global clinical development of AL001 and AL101 through to phase 2 proof-of-concept, at which point GSK will share development responsibilities for all late-stage clinical studies of the two monoclonal antibodies. The two companies will also share all costs for the ...